Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab dose optimization in adult PNH
NL-OMON60818Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Percentage change in LDH compared with baseline and Target attainment of ravulizumab concentration. Started May 2025; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON60818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60818.